[ad_1]
MALVERN, Pa., February 10, 2021 (GLOBE NEWSWIRE) – Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on the discovery, development and commercialization of gene therapies to cure blindness diseases and the development of a vaccine to fight COVID -19, today announced that it has closed the previously announced registered direct offering for the sale of a total of 3,000,000 shares of its common stock for gross proceeds of approximately 23 million dollars, before deducting placement agent fees and other offering fees payable by Ocugen.
HC Wainwright & Co. acted as the exclusive placement agent for the offering.
Ocugen intends to use the net proceeds of the offering for general corporate purposes, capital expenditures, working capital, and general and administrative expenses.
The ordinary shares described above were offered in accordance with a “provisional” registration statement (file no. 333-237456) filed with the Securities and Exchange Commission (“SEC”) on March 27, 2020 and declared effective on March 5, 2020. May 2020 These ordinary shares were only offered by means of a prospectus, including a prospectus supplement, forming part of the effective registration statement. A final prospectus supplement and related prospectus relating to the offering of common shares have been filed with the SEC. Electronic copies of the Final Prospectus Supplement and accompanying prospectus relating to the Common Share Offering can be obtained from the SEC’s website at http://www.sec.gov or by contacting HC Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by email: [email protected] or by phone: (646) 975-6996.
This press release does not constitute an offer to sell or a solicitation of an offer to buy such securities, and there will be no sale of such securities in any state or other jurisdiction in which such an offer, solicitation or sale would be illegal prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of gene therapies to cure blindness diseases and the development of a vaccine to fight COVID-19. Our revolutionary modifying gene therapy platform has the potential to treat multiple retinal diseases with a single drug – ‘one to many’, and our new biologic candidate aims to provide better therapy for patients with underserved conditions such as macular degeneration. wet age-related, diabetic macular edema and diabetic retinopathy. For more information, please visit www.ocugen.com.
Caution regarding forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. These forward-looking statements contained in this press release include, without limitation, the intended use of the net proceeds of the recorded direct offering. In some cases we may use terms such as “predict”, “believe”, “potential”, “proposed”, “continue”, “estimate”, “anticipate”, “expect”, “plan”, ” intends, “” may “,” could “,” could “,” will “,” should “or other terms that reflect the uncertainty of future events or results to identify such forward-looking statements. Such statements are subject to many important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as the market and other conditions. These and other risks and uncertainties are described in more detail in our periodic filings with the SEC, including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. the SEC. All forward-looking statements we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update any forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release. Press.
Company contact:
Ocugen, Inc.
Sanjay subramanian
Chief Financial Officer and Head of Business Development
[email protected]
Media contact:
LaVoieHealthScience
Emmie twombly
[email protected]
+ 1857-389-6042
[ad_2]
Source link